<DOC>
	<DOCNO>NCT02897869</DOCNO>
	<brief_summary>Single-center , open-label , 2-sequence , 3-period crossover drug-drug interaction study . Repeated dos POL7080 repeat dos amikacin administer alone combine . In total , 14 subject enrol obtain least 10 evaluable subject . The study consist eligibility screen period , 3 treatment period follow-up visit .</brief_summary>
	<brief_title>DDI Study Investigate Interaction Between Amikacin POL7080</brief_title>
	<detailed_description />
	<mesh_term>Amikacin</mesh_term>
	<criteria>Healthy male female ( nonchildbearing potential ) subject 18 55 year age ( inclusive ) BMI 18.030.0 kg/m2 Creatinine clearance estimate Cockroft Gault formula &gt; 80 mL/min &lt; 160 ml/min ( male ) , &lt; 150ml/min ( female ) Non smoker Normal audiogram . History suspicion alcohol and/or drug abuse last 5 year Within 2 month prior screen : exposure aminoglycoside antibiotic , chemotherapy , current use loop diuretic Regular consumption large amount xanthine Any medication inhibits active tubular secretion within 4 week prior first dose Infection human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) hepatitis C ( HCV ) Any sign renal impairment Clinically significant abnormality ( e.g . cardiovascular , laboratory value ) Clinically significant abnormal ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>